FindTrial
Sign In

Secukinumab (75 mg)

DRUG4 trials

Sponsors

Novartis Pharmaceuticals, Peking University Third Hospital

Conditions

Anklyosing SpondylitisAnkylosing SpondylitisAtherosclerotic Cardiovascular DiseaseCardiorenal Metabolic SyndromeCarotid Artery StenosisChronic Kidney DiseaseCoronary Artery DiseaseHypertension

Phase 3

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis
CompletedNCT01358175
Novartis PharmaceuticalsAnkylosing Spondylitis
Start: 2011-10-31End: 2014-12-31Updated: 2017-03-09
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
CompletedNCT01392326
Novartis PharmaceuticalsPsoriatic Arthritis
Start: 2011-09-30End: 2014-10-31Updated: 2016-02-04
16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
CompletedNCT01649375
Novartis PharmaceuticalsAnklyosing Spondylitis
Start: 2012-10-18End: 2018-09-18Updated: 2019-10-30

Phase 4

Effect of Secukinumab on Cardiorenal Outcomes in Patients With Cardiorenal Metabolic Syndrome and Atherosclerotic Cardiovascular Disease
Not yet recruitingNCT07704190
Peking University Third HospitalAtherosclerotic Cardiovascular Disease, Cardiorenal Metabolic Syndrome, Carotid Artery Stenosis +5
Start: 2026-07-15End: 2028-12-31Target: 100Updated: 2026-07-15

Related Papers

No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials
Arthritis Research & Therapy2026-04-11
Automated detection of spinal bone marrow oedema in axial spondyloarthritis: training and validation using two large phase 3 trial datasets.
2025-10-011 citations
Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis: A Subgroup Analysis of the Phase 3 FUTURE Studies.
2024-04-163 citations
P266 Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies
Lara D. Veeken2022-04-23
Effect of Secukinumab on Traditional Cardiovascular Risk Factors and Inflammatory Biomarkers: Post Hoc Analyses of Pooled Data Across Three Indications
Rheumatology and Therapy2022-03-1933 citations
Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1
BMC Musculoskeletal Disorders2021-12-1320 citations
Nonsteroidal anti-inflammatory drug-sparing effect of secukinumab in patients with radiographic axial spondyloarthritis: 4-year results from the MEASURE 2, 3 and 4 phase III trials.
2021-11-134 citations
A Pooled Analysis Reporting the Efficacy and Safety of Secukinumab in Male and Female Patients with Ankylosing Spondylitis.
2021-10-0712 citations
Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies
The Journal of Rheumatology2021-03-1516 citations
Achievement of Remission Endpoints with Secukinumab Over 3 Years in Active Ankylosing Spondylitis: Pooled Analysis of Two Phase 3 Studies
Rheumatology and Therapy2020-12-2213 citations
Secukinumab Demonstrates Sustained Efficacy and Safety in a Taiwanese Subpopulation With Active Ankylosing Spondylitis: Four-Year Results From a Phase 3 Study, MEASURE 1
Frontiers in Immunology2020-11-265 citations
Secukinumab's effect on structural damage progression in psoriatic arthritis: longitudinal mixture modelling of FUTURE-1 and FUTURE-5.
2020-11-172 citations
Treat-to-target strategy with secukinumab as a first-line biological disease modifying anti-rheumatic drug compared to standard-of-care treatment in patients with active axial spondyloarthritis: protocol for a randomised open-label phase III study, AScalate
BMJ Open2020-09-018 citations
5-year efficacy and safety of secukinumab in patients with ankylosing spondylitis: end-of-study results from the phase 3 MEASURE 2 trial.
2020-06-0119 citations
Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies.
2020-04-3033 citations
EP37 Long-term evaluation of secukinumab 150 mg in ankylosing spondylitis: 5-year end-of-study efficacy and safety results from a phase 3 trial
Lara D. Veeken2020-04-01
Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study.
2019-11-1440 citations
Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study
RMD Open2019-09-0180 citations
Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis
The Journal of Rheumatology2019-06-1529 citations
Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
Lara D. Veeken2018-11-06136 citations

13 more papers not shown